| Literature DB >> 21626816 |
N A Shamalov, L V Stakhovskaia, D V Burenchev, I V Kichuk, T V Tvorogova, A Iu Botsina, A S Smychkov, O B Kerbikov, H Moessler, P Novak, V I Skvortsova.
Abstract
The purpose of this randomized, double-blind, placebo-controlled study was to assess safety and efficacy of cerebrolysin used in dosage 50 ml in acute ischemic stroke. Forty-seven patients with ischemic stroke, aged 45-85 years, who were admitted to a clinical unit within the first 12 h after stroke onset were included in the study. A quantitative time-related MRI analysis of the dynamics of neurological deficit revealed the more rapid decrease of stroke volume to the 28th day in the group treated with cerebrolysin (45.4% versus 43.6% in the placebo-group (p < 0.05)). No side-effects of treatment with cerebrolysin was found. The results of this prospective, randomized, placebo-controlled study suggest the positive effect of cerebrolysin on the dynamics of volume lesion in patients with ischemic stroke.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21626816
Source DB: PubMed Journal: Zh Nevrol Psikhiatr Im S S Korsakova ISSN: 1997-7298